左西孟旦治疗失代偿性心力衰竭患者的临床效果观察  

Clinical observation of levosimendan in the treatment of patients with decompensated heart failure

作　　者：宋岸坚[1] 任强[1] 林雪梅[1] 陈基华[1] SONG Anjian;REN Qiang;LIN Xuemei;CHEN Jihua(Department of Cardiology,Jiangmen Central Hospital,Guangdong,Jiangmen 529000,China)

机构地区：[1]广东省江门市中心医院心血管内科,广东江门529000

出　　处：《中国医药科学》2018年第7期251-253,共3页China Medicine And Pharmacy

摘　　要：目的针对左西孟旦治疗失代偿性心力衰竭患者的治疗效果进行观察。方法随机选取我院2016年4月~2017年7月收治的失代偿性心力衰竭患者共计44例,根据入院大小号分为研究组和对比组,对比组使用盐酸多巴酚丁胺治疗,研究组使用左西孟旦治疗,对比分析两组患者心功能指标、治疗效果和不良反应发生率。结果研究组患者在SV、BNP、LVEF等心功能指标中均明显优于对比组,组间对比差异有统计学意义(P<0.05);研究组患者治疗总有效率高于对比组、不良反应发生率低于对比组,经统计学对比分析差异有统计学意义(P<0.05)。结论左西孟旦对失代偿性心力衰竭患者的治疗效果较好,安全性较高,具有较高的临床应用价值。Objective To observe the therapeutic effect of levosimendan on patients with decompensated heart failure.Methods Forty-four patients with decompensated heart failure from April 2016 to July 2017 were randomly selected and divided into study group and contrast group according to the size of admission number.The contrast group was treated with dobutamine hydrochloride,and the study group was treated with levosimendan.The cardiac function index,treatment effect and the incidence of adverse reaction were compared and analyzed in the two groups.Results The SV,BNP and LVEF in the study group were significantly better than those in the contrast group(P<0.05).The total effective rate of treatment in the study group was higher than that in the contrast group and the incidence of adverse reactions was lower than that in the contrast group,and the statistical analysis was significant(P<0.05).

关 键 词：左西孟旦 失代偿性 心力衰竭 效果 

分 类 号：R541.6[医药卫生—心血管疾病]